Nanospectra Biosciences, Inc.
8285 El Rio Street
8 articles with Nanospectra Biosciences, Inc.
Nanospectra Biosciences Announces University of Texas Medical Branch at Galveston as Clinical Trial Site
Nanospectra Biosciences, Inc. announced the addition of University of Texas Medical Branch at Galveston as the fifth trial site in its pilot feasibility study "MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue".
Nanospectra Biosciences Recognized as a ‘Houston Innovation Success’ at Congressional Healthcare Innovations Summit
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that the company was the featured innovation success at the Congressional Healthcare Innovations Summit in Houston, Texas on February 21, 2019 at Rice University
2/1/2019As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
Nanospectra Biosciences, Inc. today announced the appointment of Michael Brawer, M.D., as Chief Medical Officer (CMO). Dr. Brawer will assume responsibility for leading Nanospectra's overall clinical development, regulatory, and medical affairs activities, effective immediately.
Nanospectra Biosciences, Inc. today announced that two of its commercial partners, Sebacia, Inc. and LiteCure, LLC, have advanced towards commercialization and indicated plans for commercial launch in the United States in 2019.
Company Completes Critical Steps Towards Commercialization of AuroLase Therapy for Solid Tumor Ablation for Localized Prostate Cancer
Gold Nanoshells Help Visibly Heat And Destroy Cancer, University of Texas M. D. Anderson Cancer Center and Nanospectra Biosciences, Inc. Study